Material Transfer Agreements (MTAs)

If your business is sending or receiving samples, strains, prototypes, cell lines, compounds, data-linked specimens or other research materials, a casual email chain is usually not enough. This is where businesses often get caught. They share materials before ownership is clear, accept broad standard terms without checking publication or IP clauses, or assume the recipient cannot use the material beyond the immediate project.

Material transfer agreements (MTAs) set the legal rules for how materials can be used, stored, returned, commercialised and kept confidential. For startups, universities, biotech companies, medtech businesses, manufacturers and R&D teams, the main risk is not just losing control of a sample. It is losing control of the results, inventions and commercial opportunities connected to it. This guide explains what an MTA does, what Australian businesses should look for before they sign, and the common drafting traps that can create expensive disputes later.

Overview

A material transfer agreement is a contract used when one party provides tangible research or commercial materials to another party for testing, evaluation, validation, research or limited internal use. It should clearly say who owns the original material, what the recipient can do with it, who owns any results or improvements, and what happens when the project ends.

• Define the material precisely, including samples, derivatives, progeny, modifications and related data.
• Set the permitted use, including whether use is limited to a named project, internal research only, or broader commercial testing.
• Deal with intellectual property, including existing IP, project results, inventions, improvements and publication rights.
• Include confidentiality, privacy notice and security obligations where the material or related information is sensitive.
• Cover compliance issues, such as transport, biosafety, storage, permits and disposal requirements.
• State liability limits, indemnities, warranties and risk allocation if the material causes loss, contamination or regulatory issues.
• Specify practical end-of-term obligations, including return, destruction, ongoing record keeping and survival clauses.

What Material Transfer Agreements Mtas Means For Australian Businesses

A material transfer agreement gives Australian businesses a clear legal framework for sharing physical materials without giving away more rights than intended.

In practice, an MTA is often used where one business, research organisation or university sends biological material, chemicals, prototypes, formulations, seeds, test components or other specialised materials to another party. The transfer may be for product validation, contract research, manufacturing assessment, compatibility testing, due diligence or a joint research project.

Australian founders often focus on the shipment itself, but the real legal value usually sits around the shipment. The agreement decides what the recipient can learn from the material, what they can create from it, whether they can publish results, and whether they can use the material to compete or file IP.

When businesses commonly use an MTA

An MTA is usually relevant where the transfer is more than a simple sale of goods. If the recipient is obtaining access for a limited purpose and the provider wants ongoing control, a standard supply agreement may not be enough.

• A biotech startup sends cell lines or compounds to a contract research organisation for testing.
• A medtech company provides prototypes or coated materials to a manufacturer for technical assessment.
• A university research team shares samples with an industry partner for validation work.
• An agritech business sends seeds, strains or biological material for trials.
• A food or cosmetics business provides formulations or ingredients for lab analysis.

How an MTA differs from other contracts

An MTA is not just a confidentiality agreement and it is not always a full research collaboration agreement. A confidentiality agreement protects information. An MTA also controls possession and use of the material itself. A research collaboration agreement is broader and may cover funding, milestones, governance and commercialisation in more detail.

Some projects need more than one contract. For example, if you are sharing a material under strict use conditions while also paying a CRO to run a study, you may need an MTA plus a service agreement and a non-disclosure agreement. If the parties are genuinely developing new IP together, a separate collaboration or IP agreement may also be appropriate.

Why this matters in Australia

Australian businesses often deal with universities, hospitals, offshore counterparties and regulated industries. That means the MTA may need to work alongside privacy rules, ethics approvals, export controls, biosafety requirements, industry codes, and any contractual commitments you already owe to investors, licensors or grant providers.

If human samples, personal information or sensitive research data are involved, privacy and data protection issues may arise alongside the MTA. If patented technology, trade secrets or know-how sit behind the material, you also need the agreement to align with your broader IP strategy. Before you sign, make sure the MTA does not cut across your patent filing plans, publication restrictions or existing licence arrangements.

Legal Issues To Check Before You Sign

Before you sign a material transfer agreement, the key question is whether the document matches the commercial purpose of the transfer and properly protects your IP, confidentiality and risk position.

1. What exactly is being transferred?

The definition of the material should be specific. If it is vague, the parties may later disagree about whether the agreement covers raw samples only, or also derivatives, extracted components, data sets, modified versions and test outputs.

A good definition often needs to address:

• The original material supplied.
• Replicates, progeny, derivatives or modifications.
• Associated protocols, technical information and handling instructions.
• Related data generated from analysing the material.
• Whether third party materials or embedded licensed components are excluded.

This is where founders often get caught. A provider may think the recipient only has permission to test the sample as delivered, while the recipient assumes they can isolate, reverse engineer or develop modified versions.

2. What use is actually permitted?

The permitted use clause is usually the heart of the MTA. It should say whether the recipient can use the material for a named project only, internal evaluation only, non-clinical testing only, or a broader commercial purpose.

You should also check whether the recipient can:

• Use the material for commercial purposes.
• Use it in humans, animals or field trials.
• Transfer it to subcontractors, affiliates or consultants.
• Reproduce or modify the material.
• Use it to benchmark or develop competing products.
• Retain copies or residual amounts after the project ends.

If you are the recipient, make sure the use rights are wide enough for the actual work you need done. If you are the provider, limit the use to what you are comfortable allowing and no more.

3. Who owns the material, the results and any improvements?

Ownership clauses can make or break the commercial value of the arrangement. The provider will usually keep ownership of the original material. The harder issue is who owns results, data, inventions, improvements, modifications and new IP created through use of the material.

Common positions include:

• The provider owns the original material, and the recipient owns its raw results, subject to a licence back.
• The recipient owns project results, but any improvements to the material itself belong to the provider.
• Each party owns its background IP, and new IP is allocated based on inventorship or a negotiated split.
• Commercial use of results requires a separate licence or further agreement.

Do not rely on broad phrases like “all developments belong to the provider” without defining developments. If the recipient is paying for substantial testing or generating valuable know-how, a one-sided IP clause may not reflect the deal.

4. Can either party publish or disclose results?

Publication rights matter well beyond academia. Early disclosure can damage patent filing strategy, reveal trade secrets or affect investor diligence. An MTA should say whether results can be published, presented or disclosed, and whether the other party has a review period before publication.

If the material relates to patentable inventions, check the timing carefully before you rely on a verbal promise. Public disclosure before filing can create serious IP issues. If your project has university involvement, this point often needs especially careful drafting because academic publication expectations may differ from commercial confidentiality expectations.

5. What confidentiality protections are in place?

Most MTAs include confidentiality obligations, but the detail matters. The agreement should identify what confidential information is protected, how it can be used, who can access it, and how long the obligation lasts.

Look closely at:

• Whether oral disclosures are covered.
• Whether confidential information includes test results and observations.
• Who within the recipient organisation may access the material and information.
• Whether affiliates and subcontractors are bound on equivalent terms.
• How long confidentiality survives after termination.

6. Are there privacy or ethics issues?

If the transfer includes human tissue, patient-linked specimens or material associated with personal information, privacy and ethics issues may arise. The MTA alone may not solve those issues.

Depending on the project, you may need to consider:

• Whether the material is de-identified or still linked to individuals.
• Whether the Privacy Act 1988 applies to the handling of related information.
• Whether consent, ethics approval or institutional approvals are required.
• Cross-border disclosure issues if data or materials move offshore.

These questions can be technical. If they apply, legal advice should be coordinated with the relevant ethics, compliance or privacy team.

7. What warranties, disclaimers and liability settings apply?

Many providers supply materials on an “as is” basis and give very limited warranties. That can be reasonable for experimental materials, but the recipient should still understand the risk allocation.

Check whether the agreement deals with:

• Fitness for purpose disclaimers.
• Contamination or defect risk.
• Compliance with law and permit obligations.
• Indemnities for misuse, unauthorised transfer or unsafe handling.
• Caps on liability and exclusions for indirect loss.

If your business is handling hazardous or regulated materials, these clauses should align with your insurance obligations and operational controls.

8. What happens at the end of the project?

The end-of-term provisions should be practical and specific. If they are not, the parties may disagree about whether materials have been fully returned, destroyed or retained lawfully.

The agreement should cover:

• Whether materials must be returned or destroyed.
• How destruction is verified.
• Whether archival data or regulatory records may be retained.
• Whether confidentiality, IP, indemnity and publication restrictions continue.
• What happens if the project ends early.

Common Mistakes With Material Transfer Agreements Mtas

The most common mistake with material transfer agreements is treating them like admin paperwork instead of a document that controls future IP and commercial value.

Accepting the other party’s standard form without checking the project details

Many universities, CROs and larger counterparties have their own template MTA. Those templates may be workable, but they are often written to protect the issuing party’s position. Before you accept the provider's standard terms, check whether the clauses fit your role, your intended use and your commercial goals.

A startup receiving material for paid testing may sign terms that prohibit any commercial use, even though the entire project is commercial. A provider may sign a recipient-friendly form that gives away broad rights to improvements without realising it.

Leaving IP drafting too vague

Loose IP language creates disputes later, especially when a project produces useful data or an unexpected invention. If the agreement does not separate background IP from project IP, or does not explain what counts as an improvement, both parties may assume they own the same thing.

Clear drafting should distinguish between:

• IP each party already owns before the transfer.
• Ownership of the material itself.
• Ownership of test data and reports.
• Ownership of inventions and improvements arising from use.
• Any licence rights needed for further research or commercialisation.

Ignoring practical handling and compliance issues

Even a well-drafted IP clause will not help much if the material is mishandled, shipped incorrectly or stored in breach of protocol. Some materials require strict transport, quarantine, biosafety or chain-of-custody controls. Others degrade quickly or create contamination risks.

Founders sometimes focus on signing and forget to check the operational side before they send the material. If the agreement imposes detailed handling obligations, make sure your team and service providers can actually meet them.

Failing to deal with subcontractors and affiliates

A recipient may assume a contract laboratory or related company can access the material as part of the same project. That is not always true. If the MTA bans onward transfer, handing the material to a subcontractor could be a breach.

If third parties need access, the agreement should permit that expressly and require equivalent confidentiality, security and use restrictions.

Forgetting publication timing

Publication clauses often get less attention than ownership clauses, but timing matters. A conference abstract, investor deck or article can disclose enough to create IP problems. If the project may produce patentable outcomes, make sure review periods and filing plans are discussed early.

Not aligning the MTA with the rest of the deal

An MTA should not sit in isolation. If the broader arrangement also includes services, manufacturing, licensing, grant funding or collaboration obligations, the documents need to work together.

For example, the service agreement may say the customer owns all deliverables, while the MTA says the provider owns all improvements related to the material. If those clauses overlap, the parties may end up with conflicting rights before the work is even complete.

FAQs

Do all sample-sharing arrangements need an MTA?

No. If the transfer is a straightforward sale of goods with no ongoing use restrictions, another contract may be more suitable. An MTA is most useful where the provider wants to control use, confidentiality, IP or return of the material.

Can an MTA cover commercial use?

Yes, but only if the agreement says so. Many MTAs restrict use to internal research or evaluation. If your project has a commercial purpose, the permitted use clause should reflect that clearly before you sign.

Who usually owns improvements created from the material?

There is no automatic answer. The agreement should allocate ownership of improvements, modifications and inventions expressly. If the clause is vague, disputes are more likely, especially where the recipient generates valuable know-how or adapted versions of the material.

Is a confidentiality agreement enough instead of an MTA?

Usually not if physical materials are being transferred for limited use. A confidentiality agreement protects information, but it may not properly deal with possession, use restrictions, derivatives, return, destruction, risk and ownership of results.

What if the material is linked to personal information or human samples?

You may need more than an MTA. Privacy, consent and ethics requirements can apply depending on the nature of the material and associated data. Those issues should be checked separately under Australian privacy and compliance rules.

Key Takeaways

• Material transfer agreements (MTAs) are used to control how valuable physical materials can be used, shared, analysed, returned and commercialised.
• The most important clauses usually deal with the material definition, permitted use, confidentiality, publication, IP ownership, liability and end-of-project obligations.
• Australian businesses should check whether the MTA also needs to address privacy, ethics, biosafety, permit or cross-border compliance issues.
• Common problems include accepting standard terms too quickly, leaving IP wording vague, overlooking subcontractor access and failing to align the MTA with related services or collaboration contracts.
• Before you sign, make sure the agreement reflects the real project, not just the transfer itself, because the long-term value often sits in the results and improvements rather than the sample alone.

If you want help with IP ownership clauses, confidentiality terms, publication restrictions, liability allocation, you can reach us on 1800 730 617 or team@sprintlaw.com.au for a free, no-obligations chat.